BC cells necessitate a continual blood supply for oxygen and essential nutrients (81). Initially, during tumor growth, nutrients and oxygen are obtained via diffusion (82). However, as the tumor mass reaches a certain size, diffusion becomes insufficient to sustain growth, prompting the formation of new vasculature to support tumor growth and metastasis (81, 83). Thus, angiogenesis is critical for tumor advancement, proliferation, and metastasis. Tumor blood vessels exhibit high tortuosity, increased vascular permeability, and sluggish blood flow (62)compared to normal vessels, leading to increased local hypoxia, which in turn stabilizes HIF-1α, fostering tumor invasion and metastasis (84–87)

HIF plays a pivotal role in regulating angiogenesis ( Figure 3 ) (88, 89). BC cells exhibit elevated levels of HIF, stimulating gene expression that facilitates proliferation, metastasis, angiogenesis, and invasion (90, 91). HIF-1α is notably expressed in precursor lesions and early stages of BC (92). Suppression of the HIF-1α gene or inhibition of its transcription can hinder tumor cells from secreting vascular endothelial growth factor (VEGF) and impede tumor neovascularization (8, 93, 94).

HIF-1α shows increased expression particularly in triple-negative BC (TNBC). The nuclear factor kappa B (NF-κB) signaling pathway is activated in TNBC, promoting tumor cell proliferation, angiogenesis, and evasion of apoptosis ( Figure 3 ) (95). Tumor necrosis factor-alpha (TNF-α) or interleukin (IL)-1 activates inhibitory kappa B kinase (IKKB), leading to NF-Kb activation (96). Additionally, under chronic hypoxia in TNBC cell lines, reactive oxygen species (ROS) further activate NF-κB by degrading inhibitor of κB-α (IκBα) (97). The NF-κB pathway boosts HIF-1α mRNA expression by enhancing its transcription (98, 99). TNF-α may elevate HIF-1α expression by activating NF-κB signaling in TNBC cells and could be influenced by IL-17 (100).

In BC, HIF-1α primarily induces angiogenesis by regulating the expression of VEGF, hepatocyte growth factor (HGF), vascular cell adhesion molecule 1 (VCAM1), and VEGF receptor (VEGFR) ( Figure 3 ) (62, 101). VEGF, a critical downstream target of the HIF pathway, drives angiogenesis by influencing endothelial cell migration, proliferation, permeability, and survival (102–105). Under hypoxic conditions, HIF-1α binds to the VEGF promoter, significantly increasing VEGF mRNA levels in TNBC compared to other BC subtypes (106). HIF-1α also upregulates breast tumor kinase mRNA and protein expression, which stimulates angiogenesis via hepatocyte growth factor (107). Furthermore, HIF-1α induces overexpression of C1q binding protein (C1QBP), indirectly stimulating the NF-κB signaling cascade to upregulate VCAM1 expression and promote TNBC angiogenesis (74). Short-term hyperoxia induces ROS formation, leading to increased brain-derived neurotrophic factor expression and VEGFR receptor upregulation through HIF-1α, promoting angiogenesis (108).

Although HIF-1α predominates in BC, the HIF-2α isoform is equally crucial as a key regulator of pathophysiological angiogenesis (109). RAB11B-AS1, a long noncoding RNA (lncRNA), enhances VEGFA and angiopoietin-like 4 (ANGPTL4) expression in hypoxic BC cells in a HIF-2α-dependent manner, promoting tumor angiogenesis and metastasis (110). In conclusion, angiogenesis is a multifaceted process, and HIF-1α significantly contributes to angiogenesis in BC (62, 111).

Enhanced glucose metabolism plays a vital role in the growth and division of cancer cells, which require significant amounts of biomass and alternate energy sources to offset the diminished oxidative phosphorylation. The activity of HIF is believed to be intimately associated with glucose metabolism. Genes activated by HIF transcription include crucial components of glucose metabolism, such as glucose transporters (GLUT1 and GLUT3), enzymes involved in the glycolytic pathway (hexokinase, phosphofructokinase, aldolase, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase, enolase, pyruvate kinase, and lactate dehydrogenase [LDH]), and pyruvate dehydrogenase (PDH) kinase (PDK) ( Figure 4 ) (28, 55, 112, 113). Du et al. investigated the potential roles and mechanisms of the hypoxic MIR210HG axis, finding that MIR210HG increases HIF-1α protein levels by directly interacting with the 5’-UTR of HIF1α mRNA. This elevation in HIF-1α protein enhances the expression of enzymes related to glycolysis (pyruvate kinase M2, LDHA) and GLUT1 (114). In hypoxic conditions, HIF-1α facilitates the shift of tumor cells from oxidative to glycolytic metabolism by triggering genes that encode glucose transporters and glycolytic enzymes (115). In particular, the overexpression of HIF-1α in glucose augments glucose absorption in tumor cells through the elevation of glucose transporter levels. The modification of proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) (O-GlcNAcylation) influences glycolysis in BC cells via the HIF-1α/GLUT1 signaling pathway (81, 116). Glucose is processed through the glycolytic pathway in tumor cells, generating substantial amounts of pyruvate (117). Hexokinase 2 (HK2) serves as both the initial and rate-limiting enzyme in the glycolysis pathway (81). CircRNF20 is found to accelerate tumor progression by targeting miR-487a/HIF-1α/HK2 in BC (73). HIF-1α enhances PDK activity and blocks the transformation of pyruvate to acetyl-CoA by inhibiting PDH; thus, reducing the entry of pyruvate into the tricarboxylic acid cycle (55, 118). LDHA converts pyruvate into lactic acid, which is then transported out of the cell by the monocarboxylate transporter (MCT) (62). As cancer cell metabolism shifts to aerobic glycolysis, lactate supplants pyruvate and is expelled into the tumor microenvironment (TME), thereby fostering an immunosuppressive milieu that supports tumor cell proliferation, metastasis, and invasion (119, 120).

Glycolysis can lead to an increase in HIF-1α levels, which in turn raises VEGF expression (121). Aerobic glycolysis stimulates angiogenesis by producing lactate, which acidifies the extracellular environment and enhances VEGF expression (122). Additionally, the end products of glycolysis, lactate and pyruvate, influence VEGF expression through the augmentation of HIF-1α levels (123–125). Hence, it is postulated that the transition to glycolysis precedes angiogenesis. In summary, HIF-1α plays a crucial role in regulating glucose metabolism in BC.

Invasion and metastasis involve the spread of cancer cells from the primary tumor site to distant organs, leading to the formation of secondary tumors (81). Early estimates indicate that nearly two-thirds of cancer-related deaths and three-quarters of BC-related deaths result from metastasis (126). EMT, a process in which epithelial cells convert into mesenchymal cells through specific mechanisms, is a key aspect of tumor metastasis (127, 128). Cancer cells that undergo EMT exhibit enhanced invasive capabilities and resistance to apoptosis. Often, EMT is induced by hypoxia, with HIF-1α overexpression linked to various molecules and pathways ( Figure 5 ) (76, 129–132). Research has shown that hypoxia-induced HIF-1α expression leads to the activation of major transcription factors such as TWIST, Snail, Slug, SIP1, STAT3, and ZEB. This activation results in E-cadherin suppression and vimentin induction in BC, with HIF-1α inhibition markedly increasing E-cadherin levels (133). While E-cadherin encourages collective migration of mixed E/M phenotypes by inhibiting TGF-β, TGF-β activation promotes single-cell migration (134). CSF-1, a regulator of EMT, is influenced by hypoxia. HIF-1α induces a mixed E/M phenotype via its target gene CSF-1, facilitating collective migration (135). Additionally, hypoxia has been shown to increase Slug and Snail expression and decrease E-cadherin levels during HIF1-induced EMT through the Notch pathway (136). HIF-1α activates matrix metalloproteinases 1, 2, 9, and 14, aiding in the breakdown of extracellular matrix components and basement membrane degradation, thereby easing cancer cell migration and spread (75, 113, 130, 137, 138). Chemokine receptors 4 (CXCR4) and 3 (CXCR3), associated with invasion, angiogenesis, metastasis, and prognosis, are upregulated by HIF-1-dependent expression, enhancing cell migration and survival during cycling (139, 140). HIF signaling impacts cell extravasation by modulating genes encoding L1 cell adhesion molecules and ANGPTL4, which reduces endothelial cell adhesion (141). He et al. (2020) showed that hypoxia-induced HIF-1α regulates BC cell migration and EMT through the MiR3383p/ZEB2 axis (142). Moon et al. identified MRPL52 as a transcriptional target of HIF-1α, with MRPL52 promoting EMT, migration, and invasion in hypoxic BC cells via the ROS-Notch1-Snail pathway (143).

Recent research indicates that HIF-dependent lncRNAs may contribute to the metastatic phenotype of BC cells. Under hypoxia, lncRNA BCRT1, regulated by HIF-1α transcriptionally, promotes EMT (144). Liu et al. identified HIF-1α as a potential transcription factor for lncRNA HLA complex group 18 (HCG18), with a positive correlation between HCG18 and HIF-1α expression in BC tissue. Knockdown of HIF-1α reduced HCG18 levels in BC cells, and HIF-1α binding to specific HREs in the HCG18 promoter stimulates HCG18 expression. In vivo assays showed that decreasing HCG18 expression in MDA-MB-231 cells curbed tumor growth and lung metastasis in xenograft mouse models, highlighting HIF1α’s role as a critical regulator of hypoxia-induced EMT and metastasis (145). Metastasis poses a significant prognostic challenge in BC, and targeting HIF-1α to inhibit BC metastasis presents a viable strategy.

Apoptosis, a genetically controlled form of cell death, is crucial for normal cellular regulation. Cancer cells, however, often evade apoptosis, contributing to chemotherapy resistance or tumor relapse. This evasion involves a complex interplay of proteins and cytokines. Research indicates that HIF-1α exhibits a dual role in apoptosis, capable of both inducing and counteracting it (1). HIF-1α can induce and antagonize apoptosis ( Figure 5 ). The proapoptotic effects of HIF-1α involve the regulation of genes such as BNIP, Bid, Bax, Bak, Bad, BNIP3, NIX, and NOXA (146), whereas its antiapoptotic effects are seen in the modulation of Bcl-2, Bcl-xL, and myeloid cell leukemia (Mcl-1) expression (1). In MDA-MB-231 cells treated with paclitaxel, a HIF-1α-dependent alteration in the expression of various pro- and antiapoptotic genes was observed. Under hypoxic conditions, compared to normoxic conditions with paclitaxel, a reduction in proapoptotic gene expression (BAK1, CASP3, CASP8, CASP10, and TNFRSF10A) was noted (147).

HIFs also play a significant role in autophagy, another programmed cell death mechanism ( Figure 5 ). In MCF7 cells subjected to radiation, HIF-1α induces autophagy by inhibiting the PI3K/AKT/mTOR/p70 pathway and increases the expression of Mcl-1 and BNIP-3 (148). Mcl-1 participates in the neutralization of proapoptotic proteins, inhibiting cytochrome c release from mitochondria (149), while BNIP-3, a mitochondrial protein in the Bcl-2 family, triggers selective mitophagy by releasing Beclin-1 to initiate autophagy (150, 151). The interplay between autophagy and apoptosis is crucial, especially for inducing cell death in antiapoptotic BC cell lines (152).

Cancer-associated fibroblasts (CAFs) interact with tumor cells to promote tumor cell growth and metastasis. CAFs, mainly normal interstitial fibroblasts (NFs), are the most abundant cell type in the stroma of breast cancer (153, 154). In breast cancer tumors, only a small fraction of fibroblasts are quiescent; these fibroblasts are responsible for the structural integrity of the extracellular matrix (ECM) and its nutrient supply and contribute to wound healing (155). However, most fibroblasts exhibit an activated phenotype characterized by producing various extracellular matrix components and paracrine mediators (156). Among the many mechanisms involved in transforming NFs to CAFs, local hypoxia has been proven to drive the differentiation of NFs into activated myofibroblasts by triggering the formation of reactive oxygen species (ROS) (157, 158). Additionally, CAF activation is reversible: chronic hypoxia inactivates CAFs, leading to the loss of contractility, reduction of surrounding extracellular matrix remodeling, and ultimately damage CAF-mediated cancer cell invasion (159). Studies have shown that hypoxia-dependent deletion of PHD2 suppresses tumor growth and reduces the metastatic activity of CAFs (160, 161). Hypoxia inhibited prolyl hydroxylase domain protein 2 (PHD2), resulting in the stabilization of HIF-1α, reduced expression of αSMA and periostin, and decreased myosin II activity. Treatment with the PHD inhibitor DMOG in an orthotopic breast cancer model significantly reduced spontaneous metastasis to the lungs and liver, which correlated with decreased tumor stiffness and fibroblast activation (159). Another study revealed that the loss of PHD2 is associated with normalization of the vasculature, reduced CAF activation, and decreased intravascular invasion of metastases (161). These findings suggest that blocking PHD2 in CAFs may be a novel strategy for inhibiting prometastatic signals in the breast cancer tumor microenvironment.

In fact, CAFs have been shown to regulate metabolic interdependency between cancer cells and their surrounding microenvironment through the action of HIF (162). HIF-1α is involved in regulating biventricular metabolic symbiosis between synthetic metabolic cancer cells and catabolic stromal fibroblasts (163). The enhanced glycolytic rate shown by CAFs is partially dependent on HIF signaling (164). Furthermore, the high-energy metabolic byproducts produced by catabolic CAFs are taken up by tumor cells to support their high anabolic demands. The increased metabolic flux in cancer cells generates ROS, which then propagate throughout the tumor microenvironment and through CAFs to promote HIF-dependent metabolic reprogramming (165).

Tumor immune escape, where cancer cells avoid detection and destruction by the host immune system (166), is facilitated under hypoxic conditions through HIF-1α overexpression( Figure 5 ) (167). HIFs increase CD47 immunoglobulin expression and hinder T cell proliferation and activation by attracting myeloid-derived suppressor cells (28). Changes in the expression of CD47, CD73, and PDL1 in TNBC cells treated with chemotherapy agents like carboplatin, doxorubicin, gemcitabine, or paclitaxel enhance cancer cells’ ability to evade both innate and adaptive immune responses (168). Increased PDL1 mRNA expression in human TNBC cell lines was linked to elevated HIF-1α expression due to endoplasmic reticulum oxidoreductase 1-α (ERO1-α), with ERO1-α knockdown significantly reducing PDL1-mediated T-cell apoptosis, suggesting avenues for therapeutic intervention in hypoxia-mediated immune resistance (169).

Regulatory T cells (Tregs), which suppress immune responses through cytokines and metabolites, play a role in tumor development (170–173). In TNBC, HIF-1α modulates Tregs’ immunosuppressive functions and aggregation by regulating forkhead box P3 (FoxP3) and C-X-C motif CXCR4. HIF-1α enhances FoxP3 expression by binding to HREs and indirectly increases CXCR4 expression; thus, supporting immunosuppression (174). Moreover, M2 macrophages, known for their immunosuppressive capabilities through IL-10 and TGF-β release, are influenced by HIF-1α (175). This factor drives the polarization of tumor-associated macrophages (TAMs) towards an M2 phenotype, creating an immunosuppressive microenvironment. It has been shown that TAMs in TNBC are more likely to adopt an M2 phenotype compared to other BC subtypes (176, 177). HIF-1α, present in BRCA1-IRIS overexpressing TNBC cells, secretes high levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), recruiting and polarizing macrophages towards an M2 phenotype; thus, facilitating immune escape (178, 179). HIF-1α’s ability to polarize TAM to M2 by regulating GM-CSF and macrophage CSF-1 in TNBC underscores its role in promoting immune evasion. HIF can also lead to extracellular acidification by regulating the expression of MCT4, which not only diminishes immune response efficiency but also impacts the efficacy of anticancer drugs (180).

Based on their genomic locations, long noncoding RNAs (lncRNAs) are categorized into five types: antisense, sense, intergenic, intronic, or bidirectional. The location of lncRNAs can be specific to the nucleus, the cytoplasm, or both (25, 181). The expression of lncRNAs is regulated similarly to that of protein-coding RNAs, through mechanisms such as epigenetic modification, gene transcription, and post-transcriptional regulation (182). In tumors, lncRNAs are often abnormally expressed and play roles in the regulation of tumor proliferation, invasion, metastasis, metabolism, angiogenesis, and survival (183, 184). Certain noncoding RNAs can influence tumor-related biological processes by regulating HIF-1α ( Figure 6 ) (25, 185, 186). For instance, LINC00649 enhances the stability of HIF-1α mRNA and protein expression by interacting with the nuclear factor 90 (NF90)/NF45 complex (187). MIR210HG specifically impacts triple-negative breast cancer (TNBC) by regulating HIF-1α at the translation level, thereby increasing HIF-1α protein expression and influencing the expression of glycolysis genes (114). MicroRNAs (miRNAs) exert a dual regulatory effect on HIF-1α, both promoting and inhibiting its expression. Saatci et al. identified eight common miRNAs that target HIF-1α, lysyl oxidase (LOX), and ITGA5, with miR-142–3p and miR-128–3p showing negative correlation with the expression of HIF-1α, LOX, and ITGA5. Hypoxia can inhibit miR-142–3p, leading to increased HIF-1α mRNA and protein expression, activating the FAK/Src signaling pathway, and triggering chemotherapy resistance in TNBC (188). However, the regulatory mechanism of miR-142–3p on HIF-1α remains unclear. Overexpression of miR-101 decreases VHL levels, stabilizing HIF-1α and inducing VEGFA expression, ultimately enhancing TNBC invasiveness (189). Thus, noncoding RNA regulates HIF-1α expression in TNBC by maintaining the stability of the HIF-1α protein and regulating the stability and translation level of HIF-1α mRNA.

In BC treatment options vary by subtype and include surgery, endocrine therapy, chemotherapy, radiotherapy, and targeted therapy, with drug therapy playing a crucial role depending on the tumor classification. However, drug resistance presents a significant challenge in BC treatment (190–192), often due to inherent or acquired resistance over time (193). Hypoxia is a common characteristic of both primary and metastatic BC (194), with HIF-1α expression in tumor tissues associated with poor prognosis and drug resistance ( Figure 7 ) (132). Research indicates that HIF-1α may contribute to resistance against conventional therapies via various signaling pathways, including drug efflux, tumor stem cell enrichment, autophagy, and apoptosis (192, 195), necessitating further investigation into HIF-1α-induced drug resistance mechanisms in BC.

Drug efflux transporters such as MDR1, multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP) are directly regulated by HIF-1α ( Figure 7 ), encoded by the ATP-binding cassette (ABC) transporters ABCB1, ABCC1, and ABCG2, respectively. Their promoters contain HREs sensitive to HIF-1α transcriptional regulation (196). The link between these transporters and drug resistance in BC has been extensively studied (197–199), with all three proteins inducing drug resistance by facilitating drug efflux from tumor cells. Studies have shown that hypoxia-induced MDR1 expression can be significantly reduced by inhibiting HIF-1 expression with antisense oligonucleotides (200).In a separate investigation, 41% of BC tumors exhibited increased levels of MDR1, leading to a threefold higher likelihood of chemotherapy failure (201). Taxanes and anthracyclines represent the primary chemotherapy agents for BC treatment. The upregulation of MDR1, also referred to as P-glycoprotein or Pgp, contributes to resistance against taxanes and anthracyclines (202). The activation of HIF-1α enhances the resistance of BC cells to these drugs (147, 203, 204). The genes ABCC1 and ABCG2, which encode MRP1 and BCRP, respectively, possess hypoxia response elements (HREs) upstream of their coding sequences. The deletion of these elements can prevent hypoxia-induced activation (196, 205). MRP1 is elevated in cells with activated HIF-1α, and this effect can be reversed by HIF-1α siRNA, indicating that ABCC1 is a direct target of HIF-1α. Another investigation discovered that HIF-1α binds to the HRE region of the BCRP promoter in LTLTCa cells, with significantly increased binding observed in the presence of CoCl₂ (206). The expression of BCRP correlated with the degree of drug resistance to irinotecan and topotecan (207). Hence, it is proposed that the expression and stability of HIF-1α can enhance the mRNA and protein levels of MDR1, MRP1, and BRCP, thereby contributing to HIF-1α-mediated drug resistance.

Autophagy has been shown to increase resistance to endocrine and cytotoxic drugs in BC (208–210). HIF-1α can activate various molecular mechanisms, such as inducing PTP-PEST expression and activating AMPK, which in turn increases BNIP3 expression. This disrupts the interaction between Beclin-1 and Bcl-2 and induces autophagy, thereby increasing BC cells’ resistance to drugs like adriamycin (211, 212). Additionally, endocrine therapies, including tamoxifen and flurvist, have been found to increase autophagy markers in drug-resistant BC cells (213, 214). Thus, HIF-1α plays a role in inducing BC resistance to both endocrine and cytotoxic drugs by upregulating autophagy.

Apoptosis, leading to cell death, is a crucial outcome of most cancer treatments. Cancer cells, however, have developed mechanisms to evade apoptosis, contributing to resistance to chemotherapy or recurrence of tumors (215). This evasion involves various proteins and cytokines, including the Bcl-2 family, apoptosis inhibitor proteins, and the caspase family, along with cytochrome c and proteases (146). HIF-1α plays a direct role in the regulation of apoptosis, exhibiting both proapoptotic and antiapoptotic effects (146). The proapoptotic actions of HIF-1α include the downregulation of proapoptotic members of the Bcl-2 family, such as BNIP3, NIX, and NOXA, while its antiapoptotic effects involve increasing the levels of antiapoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1, and decreasing the levels of proapoptotic proteins such as Bid, Bax, and Bak (216–218). In breast cancer (BC) cells, alterations in apoptotic activity following HIF-1α activation are associated with increased drug resistance (147, 219, 220), though the precise mechanisms warrant further investigation.

Stem cells play a significant role in BC, driving tumor progression and metastasis, and displaying inherent resistance to chemotherapy and radiotherapy (221, 222). These cells can enhance drug efflux, increase drug metabolism in the tumor, activate survival pathways like Notch and Hedgehog, and dampen apoptosis signaling, all contributing to chemoresistance (223). HIF-1α directly upregulates genes such as NANOG, SOX2, KLF4, and OCT4, which inhibit differentiation and maintain a stem cell-like phenotype (203, 224). Furthermore, HIF-1α supports the survival of breast cancer stem cells (BCSC) by inducing ROS-dependent expression of HIF-1α and HIF-2α, leading to HIF-mediated expression of IL-6, IL-8, and MDR1. Exposure of MDA-MB-231, SUM-149, and SUM-159 cells to paclitaxel increased the percentage of ALDH+ cells, indicative of stem cell characteristics, by twelvefold in vitro and in vivo (203). Therefore, HIF-1α activation promotes the proliferation and enrichment of tumor stem cells, contributing to drug resistance.

To overcome HIF-1α-dependent drug resistance, strategies involve directly or indirectly targeting HIF-1α with inhibitors (225). Direct inhibitors of HIF-1α target protein-protein/DNA interactions, impacting DNA binding, transcriptional activity of HIF-1α, heterodimerization with HIF-1β, and interactions with transcriptional coactivators (226–230). Indirect inhibitors aim to downregulate HIF-1α transcription or translation, reduce HIF-1α stability, or prevent its degradation, offering potential pathways to mitigate drug resistance in cancer treatment.

Numerous studies have highlighted the potential of HIF-1α inhibitors and compounds targeting the HIF-1α pathway, demonstrating their effectiveness in vitro (62, 81)( Table 2 ). For instance, treatment of MDA-MB-231 cells with the PHD inhibitor molidustat, which stabilizes HIF, resulted in reduced viability, growth, clone formation, cell cycle arrest, and increased chemosensitivity, indicating potential anticancer activity of HIF (249) Among 68 newly synthesized arylformamide compounds, compound 30 m showed the most potent inhibitory activity against HIF-1α with minimal cytotoxicity, effectively reducing hypoxia-induced HIF-1α protein accumulation (81, 250). However, clinical trials have failed to show the effect of HIF-1α inhibitors in BC treatment (81, 251)( Table 3 ). Preliminary data published in 2013 showed some clinical efficacy of digoxin in patients with stages I–III BC. However, the treatment window of the drug is narrow; serum levels exceeding 1–2 nM produce significant side effects. So far, no follow-up data are available (192, 252). The differential expression of HIF-1α and HIF-1α inhibitor monotherapy may be the factors limiting the efficacy of anti-HIF-1α therapy (1). Yu et al. discussed the lack of clinical effectiveness of HIF-1α inhibitors (230). First, although both HIF-1α and HIF-2α are involved in cancer progression, most inhibitors have targeted only HIF-1α. Therefore, the role of HIF-2α in drug resistance needs to be understood. Second, patient selection contributes to the success of clinical trials. Accuracy in the measurement of tumor HIF-1α may help to better distinguish responders from non-responders. Finally, although hypoxia varies between and within different BC subtypes, evidence suggests that the hypoxia of the patient’s tumor itself is different (253). This heterogeneity may be the main determinant of the overall drug response. Considering the limitations of HIF-1α inhibitors, a combination of HIF-1α inhibitors with chemotherapeutic drugs or other agents may improve outcomes. A preclinical study indicated that digoxin enhances the sensitivity of triple-negative breast cancer cell lines to paclitaxel and gemcitabine in vivo (203). Interestingly, molidustat has been found to enhance the cytotoxicity of gemcitabine in MDA-MB-231 cells (249). However, currently, the related combination therapy of BC is in the preclinical stage, and thus, a clear conclusion cannot be drawn. The latest HIF-1α drug delivery system is based on nanocarriers that can improve targeting specificity, overcome solubility problems, reduce drug toxicity, and maintain safe drug concentrations. Furthermore, the mode of drug administration also affects the efficacy of HIF-1α-related drugs and should be investigated in future research (81). In conclusion, the results on BC cell lines show that aspects, such as comparison of HIF-1α and HIF-2α inhibition, double vs. single isomer inhibition, different statuses of hormone receptors, metastasis, and other unexplored issues, should be considered. Thus, we need to understand the role of HIFs in BC before targeting them for clinical application (55).